에 대한 최신 뉴스 Vivos Therapeutics (NASDAQ:VVOS) 주식

Vivos Therapeutics

Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. The Vivos systme is an therapeutic protocol, which often combines the use of customized oral appliance specifications and proprietary clinical treatments developed by company and prescribed by specially trained dentists in cooperation with their medical colleagues.

Equities

News

Markets

NVDA

SOFI

TMUS

TSLA

VVOS

수요일 주식 시장은 연방준비제도(연준)의 0.5% 금리 인하 발표로 인해 하락세로 돌아섰다. 이는 2020년 3월 이후 처음으로 미 중앙은행의 매우 기대받던 금리 인하 사이클의 시작을 알리는 것이다.

수요일 주목받은 주식 5종목: 엔비디아, T-모바일, 비보스 테라퓨틱스, 소파이 및 테슬라

Vivos Therapeutics Inc

Jefferies analyst Omar Nokta maintains Ardmore Shipping (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASC#NYSE">ASC</a>) with a Buy and maintains $17 price target.

Price Target

Analyst Ratings

Jefferies Maintains Buy on Ardmore Shipping, Maintains $17 Price Target

Moderna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) is set to release its fourth-quarter earnings on Friday before the opening bell. Here's a look at what to <a href="https://www.benzinga.com/25/01/43306674/trumps-hhs-pick-robert-kennedy-jr-begins-senate-confirmation-hearings">expect in the report.&nbsp;</a>
What To Watch: Investors will be looking for updates on Moderna&#8217;s portfolio of mRNA-based vaccines and treatments across infectious diseases, immuno-oncology and rare diseases. COVID-19 vaccine demand and sales will be on watch.&nbsp;
Bird flu continues to spread through wild birds, poultry farms and cattle herds and updates on Moderna's development of an avian flu vaccine candidate should be watched closely.&nbsp;
Read Next: <a href="https://www.benzinga.com/25/02/43703014/robert-f-kennedy-confirmed-as-trump-secretary-of-health">Robert F. Kennedy, Vaccine Skeptic, Confirmed As Trump&#8217;s Secretary Of Health: Health Care Stocks To Watch</a>
Outspoken vaccine skeptic Robert F. Kennedy was sworn in as the<a href="https://www.benzinga.com/25/02/43703014/robert-f-kennedy-confirmed-as-trump-secretary-of-health"> new secretary</a> of Health and Human Services on Thursday and may enact policy changes that could affect regulations and Moderna's business. Executives may offer some commentary in the company's earnings call scheduled for 8 a.m. ET on Friday.&nbsp;&nbsp;
What Else: Goldman Sachs analyst Salveen Richter <a href="https://www.benzinga.com/25/01/43314068/moderna-stock-is-sliding-wednesday-heres-why">recently downgraded </a>Moderna from Buy to Neutral and lowered the price target from $99 to $51, citing lower conviction following a second product revenue guidance adjustment from the company.
According to estimates from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, analysts expect Moderna to report quarterly losses of $2.68 per share and revenue of $942.84 million. The company has beat consensus estimates on the top and bottom lines for the last four consecutive quarters.&nbsp;
MRNA Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Moderna shares ended Thursday's session up 4.54% at $31.92.&nbsp;
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/social-media/25/02/43535256/palantir-adds-elon-musks-ai-chatbot-grok-to-aip">Palantir Adds Elon Musk&#8217;s AI Chatbot Grok To AIP</a></li>
</ul>
Image: Shutterstock

Earnings

Health Care

Previews

Politics

Movers

General

MRNA

Moderna Q4 Earnings Preview: COVID-19 Vaccine Sales, Bird Flu Vaccine Candidates On Watch

Canaccord Genuity analyst Joseph Vafi maintains Repay Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPAY#NASDAQ">RPAY</a>) with a Buy and maintains $13 price target.

RPAY

Canaccord Genuity Maintains Buy on Repay Holdings, Maintains $13 Price Target

Canaccord Genuity analyst Joseph Vafi maintains Pagaya Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGY#NASDAQ">PGY</a>) with a Buy and maintains $25 price target.

Canaccord Genuity Maintains Buy on Pagaya Techs, Maintains $25 Price Target

Tigress Financial analyst Ivan Feinseth maintains Mastercard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>) with a Strong Buy and raises the price target from $550 to $685.

Tigress Financial Maintains Strong Buy on Mastercard, Raises Price Target to $685

Seaport Global analyst Mark Weintraub upgrades Packaging Corp of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PKG#NYSE">PKG</a>) from Neutral to Buy and announces $250 price target.

Upgrades

Seaport Global Upgrades Packaging Corp of America to Buy, Announces $250 Price Target

Citigroup analyst Joanne Wuensch maintains GE HealthCare Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEHC#NASDAQ">GEHC</a>) with a Buy and raises the price target from $103 to $110.

GEHC

Citigroup Maintains Buy on GE HealthCare Techs, Raises Price Target to $110

Maxim Group analyst Jason McCarthy maintains INmune Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) with a Buy and raises the price target from $22 to $30.

INMB

Maxim Group Maintains Buy on INmune Bio, Raises Price Target to $30

Maxim Group analyst Anthony Vendetti maintains Nutex Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUTX#NASDAQ">NUTX</a>) with a Buy and raises the price target from $50 to $75.

NUTX

Maxim Group Maintains Buy on Nutex Health, Raises Price Target to $75

Lake Street analyst Ben Klieve maintains Chefs' Warehouse (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHEF#NASDAQ">CHEF</a>) with a Buy and raises the price target from $60 to $68.

CHEF

Lake Street Maintains Buy on Chefs' Warehouse, Raises Price Target to $68

Nukkleus has also submitted a Form S-1 registration statement registering for resale the shares of common stock issued or issuable in connection with its recent &nbsp;$10 million private placement which further reinforced its financial foundation for the Star 26 acquisition and future expansion.

NUKK

Nukkleus Formally Submits Preliminary Proxy To SEC With Respect To Proposed Acquisition Of Star 26 Capital

Lake Street initiates coverage on TriSalus Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLSI#NASDAQ">TLSI</a>) with a Buy rating and announces Price Target of $10.

Initiation

TLSI

Lake Street Initiates Coverage On TriSalus Life Sciences with Buy Rating, Announces Price Target of $10

It is payable on March 26, 2025 to stockholders of record as of the close of business on March 14, 2025.

Dividends

Meta Platforms Boosts Quarterly Cash Dividend By 5% From $0.50 To $0.525 Per Share

Loop Capital analyst Garik Shmois maintains Martin Marietta Materials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLM#NYSE">MLM</a>) with a Buy and lowers the price target from $680 to $645.

Loop Capital Maintains Buy on Martin Marietta Materials, Lowers Price Target to $645

Loop Capital analyst Alan Gould maintains Reddit (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) with a Buy and raises the price target from $180 to $210.

RDDT

Loop Capital Maintains Buy on Reddit, Raises Price Target to $210

Jefferies analyst Randal Konik maintains SharkNinja (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SN#NYSE">SN</a>) with a Buy and raises the price target from $150 to $175.

Jefferies Maintains Buy on SharkNinja, Raises Price Target to $175

Canaccord Genuity analyst Jon Young maintains Staar Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>) with a Hold and lowers the price target from $28 to $17.

STAA

Canaccord Genuity Maintains Hold on Staar Surgical, Lowers Price Target to $17

Canaccord Genuity analyst Kyle Mikson maintains 10x Genomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXG#NASDAQ">TXG</a>) with a Buy and lowers the price target from $20 to $18.

Canaccord Genuity Maintains Buy on 10x Genomics, Lowers Price Target to $18

This dividend is payable on March 5, 2025 to shareholders of record on February 24, 2025. This dividend rate equates to an annualized dividend of $1.87 per share.

CHCT

Community Healthcare Trust Boosts Quarterly Dividend From $0.4650 To $0.4675 Per Share

Offerings

Gen Digital Prices $950M Of Its 6.25% Senior Notes Due 2033, Which Were Offered In Private Offering

Vivos surges on FDA nod for pediatric sleep apnea device

Vivos Therapeutics announces $4.3M registered direct offering of common stock

Vivos Therapeutics, Inc. ( ($VVOS) ) has released its Q3 earnings. Here is a breakdown of the information Vivos Therapeutics, Inc. presented to its...

Vivos Therapeutics Reports Revenue Growth and Strategic Milestones

Vivos Therapeutics, Inc. (VVOS) Q3 2024 Earnings Call Transcript

Vivos Therapeutics GAAP EPS of -$0.40, revenue of $3.86M

Vivos Therapeutics (VVOS) has entered into definitive agreements for the purchase and sale of an aggregate of 709,220 shares of its common stock at...

Vivos to sell 709,220 shares at $4.935 in registered direct offering

Check out this morning's top movers from around Wall Street, compiled by The Fly.&nbsp; HIGHER – Despegar.com&nbsp;(DESP) up 33% after Prosus annou...

Morning Movers: Despegar surges following deal to be acquired by Prosus

Vivos Therapeutics announces sale of up to 854,332 shares by selling stockholders

Vivos Therapeutics announces up to $50M mixed shelf offering

16:27 EST Vivos Therapeutics (VVOS) files $50M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving ...

Vivos Therapeutics files $50M mixed securities shelf

APLT

DESP

HNDAF

PLYA

Penny Stocks

Press Releases

Vivos Therapeutics Announces Positive Results From 7-Month Multi-Site Pilot of its New Provider-Based Marketing and Distribution Model

Vivos Therapeutics Schedules Release of Second Quarter 2024 Financial Results and Conference Call

Vivos Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update

Vivos Therapeutics Receives Groundbreaking FDA 510(k) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea and Snoring

FDA Approval Sends Shares of this Healthcare Company Higher

Vivos Therapeutics Announces Pricing of $4.3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

Vivos Therapeutics Granted CPT® Coverage and Reimbursement Codes for All Vivos CARE Oral Medical Devices From American Medical Association

Vivos Therapeutics Schedules Release of Third Quarter 2024 Financial Results and Conference Call

Vivos Therapeutics Reports Third Quarter 2024 Financial Results and Provides Operational Update

Vivos Therapeutics Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

American Shared Hospital Services Common Stock

American Shared Hospital

Biodesix

Cryo-Cell International, Inc. Common Stock

Cryo-Cell International

Enzo Biochem, Inc. Common Stock ($0.01 Par Value)

Enzo Biochem

Euda Health Holdings Limited - Ordinary Shares

EUDA Health Holdings

Kindly MD

23andMe Holding

Mobile-health Network Solutions - Class A Ordinary Shares

Mobile-health Network

ModivCare

MSP Recovery, Inc. - Class A Common Stock

MSP Recovery

NewGenIvf Group Limited - Class A Ordinary Shares

NewGenIvf Group

Nutex Health

Ontrak

Performant Healthcare, Inc. - Common Stock

Performant Healthcare

P3 Health Partners Inc. - Class A Common Stock

P3 Health Partners

Prenetics Global Limited - Class A Ordinary Share

Prenetics Global

Precipio

SHL Telemedicine Ltd - American Depositary Shares

SHL Telemedicine

Syra Health

Ascendiant Capital

Alliance Global Partners

수요일 주식 시장은 연방준비제도(연준)의 <a href="https://www.benzinga.com/economics/macro-economic-events/24/09/40926026/federal-reserve-delivers-bold-0-5-rate-cut-signals-further-easing-ahead">0.5% 금리 인하 발표</a>로 인해 하락세로 돌아섰다. 이는 2020년 3월 이후 처음으로 미 중앙은행의 매우 기대받던 금리 인하 사이클의 시작을 알리는 것이다.
다우존스 산업평균지수는 0.25% 하락한 41,503.10으로 마감했으며, S&amp;P 500은 0.3% 하락한 5,618.26으로 거래를 마쳤다. 나스닥도 0.3% 하락하여 17,573.30으로 마감했다.
수요일 하루 동안 소매 투자자들과 트레이더들의 주목을 받은 주요 주식들은 다음과 같다:
엔비디아 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)
엔비디아의 주식은 $113.37로 1.92% 하락 마감했다. 거래 중 최고가는 $117.7, 최저가는 $113.22였다. 해당 주식의 52주 최고가는 $140.76, 최저가는 $39.23다. 이 거대 기술 기업은 소프트웨어와 클라우드 컴퓨팅 서비스를 강화하기 위해 옥토AI(OctoAI) 스타트업을 1억 6,500만 달러에 <a href="https://www.benzinga.com/m-a/24/09/40926078/nvidia-considers-165m-octoai-acquisition-aims-to-strengthen-ai-and-cloud-dominance">인수</a>하는 것을 고려하고 있다.
T-모바일 US (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>)
T-모바일의 주식은 $196.68으로 2.97% 하락 마감했다. 거래 중 최고가는 $206.1, 최저가는 $195.47였다. 해당 주식의 52주 최고가는 $206.31, 최저가는 $135.82이다. 이 회사는 엔비디아, 에릭슨(Ericsson) 그리고 노키아(Nokia)와의 <a href="https://www.benzinga.com/markets/equities/24/09/40925493/t-mobile-partners-with-nvidia-ericsson-and-nokia-to-pioneer-ai-driven-mobile-networks">파트너십</a>을 발표하여 AI 기반 모바일 네트워크를 선도하고, 오픈AI와의 협약을 통해 고객 경험을 혁신하였다.
비보스 테라퓨틱스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VVOS#NASDAQ">VVOS</a>)
비보스 테라퓨틱스의 주식은 $4.13으로 47.50% 급등하여 마감했다. 거래 중 최고가는 $5.95, 최저가는 $3.02였다. 해당 주식의 52주 최고가는 $48.79, 최저가는 $1.91이다. 미국 식품의약국(FDA)은 <a href="https://www.benzinga.com/news/24/09/40920621/vivos-therapeutics-says-it-is-poised-to-disrupt-pediatric-sleep-apnea-market-secures-fda-approval-fo">소아 수면 무호흡증 시장을 혁신할</a> 기회를 제공하는 이 회사의 주력 구강 의료 기기에 510(k) 허가를 승인했다.
소파이 테크놀로지스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOFI#NASDAQ">SOFI</a>)
소파이의 주식은 $8.11로 0.12% 하락 마감했다. 거래 중 최고가는 $8.53, 최저가는 $8.04였다. 해당 주식의 52주 최고가는 $10.49, 최저가는 $6.01이다. 투자자들이 연준의 <a href="https://www.benzinga.com/fintech/24/09/40928342/what-happened-with-sofi-stock-today">금리 인하를 예상</a>함에 따라 주식이 활발히 거래되었다.
테슬라 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)
테슬라의 주식은 $227.87로 0.48% 상승 마감했다. 거래 중 최고가는 $234.57, 최저가는 $226.55였다. 해당 주식의 52주 최고가는 $273.93, 최저가는 $138.8이다. 주식이 상승한 것은 연준의 <a href="https://www.benzinga.com/news/24/09/40927218/tesla-shares-surge-amid-fed-rate-cut-and-cybertruck-developments">금리 인하 결정</a>에 대한 시장의 전반적인 반응 때문일 가능성이 높다.
Photo by Phongphan on Shutterstock
벤징가는 <a href="Premarket Movers &amp; News">상위 프리마켓 동향 및 뉴스</a>로 하루 거래를 준비하세요.
이 기사는 <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a>에 의해 생성되고 <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>에 의해 편집되었습니다.
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Vivos Therapeutics

뉴스

에 대한 최신 뉴스 Vivos Therapeutics (NASDAQ:VVOS) 주식

목요일, 9월 19, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌